Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863820 | 0.81 | GSK3B (0.49) | MAOBAPPNR4A2 | |
| SCHEMBL693492 | 0.81 | MAOB (0.40) | MAOBAPP | |
| SCHEMBL863891 | 0.77 | MAOB (0.66) | MAOBNR4A2PARP10 | |
| SCHEMBL697362 | 0.75 | MAOB (0.61) | MAOBAPPNR4A2PARP10 | |
| SCHEMBL17514987 | 0.74 | GSK3B (0.40) | MAOBAPPNR4A2 | |
| SCHEMBL864294 | 0.73 | MAPK1 (0.52) | CYP11B2CYP11B1 | |
| SCHEMBL17456350 | 0.73 | CYP3A4 (0.38) | — | |
| SCHEMBL864046 | 0.72 | LOXL2 (0.49) | MAOBAPPNR4A2 | |
| SCHEMBL694419 | 0.72 | F2 (0.45) | MAOBAPP | |
| SCHEMBL3228557 | 0.71 | MAOB (0.56) | MAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077847-A1 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS | LIPG, LIPA, LIPE | MAOB 1021/4885CYP11B2 1768/4885CYP11B1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.